XML 351 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Investments in Associates - Summary of financial information of Gelesis (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of associates [Line Items]      
Non-current assets $ 316,454 $ 444,197  
Current assets 386,192 501,809  
Non-current liabilities 58,172 135,725  
Current liabilities 96,885 226,135  
Share of associate loss allocated to long-term interest (see Note 6) (96,700)    
Investment in associates - equity method 9,147 0 $ 0
Revenue 15,618 17,388 11,768
Total comprehensive income/(loss) for the year (37,444) $ (62,709) $ 5,037
Reversal of equity method losses recorded against LTIs (due to decrease in LTI fair value) $ 4,406    
Gelesis      
Disclosure of associates [Line Items]      
Percentage ownership interest 22.50% 42.00% 47.90%
Non-current assets $ 333,040 $ 357,508  
Current assets 23,495 66,092  
Non-current liabilities 99,053 120,786  
Current liabilities 80,010 537,432  
Non controlling interests and options issued to third parties (46,204) (14,216)  
Net assets (deficit) attributable to shareholders of Gelesis Inc. 131,268 (248,834)  
Group's share of net assets (net deficit) 29,504 (104,527)  
Goodwill 3,858 7,211  
Impairment of investment (28,452) (37,495)  
Share of associate loss allocated to long-term interest (see Note 6) 0 96,709  
Unrecognized equity method losses 0 38,101  
Investment in associates - equity method 4,910 0  
Revenue 25,767 11,185 $ 21,442
Loss from continuing operations (100%) (111,567) (271,430) (71,157)
Total comprehensive income/(loss) for the year (112,285) (273,005) (70,178)
Share of net loss in Gelesis (24,306) (73,703) (34,117)
Group's share of total comprehensive loss - limited to net investment amount $ (24,472) (73,703) $ (33,648)
Unrecognised share of losses of associates, other comprehensive loss   $ 700